Print Page  Close Window

Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle  
09/14/16Allergan to Acquire Vitae Pharmaceuticals Adding Innovative Development Programs for Dermatologic Conditions
- Acquisition Adds Differentiated Development Programs to Strengthen Allergan's Medical Dermatology Pipeline - - VTP-43742, First-in-Class Oral RORγt Inhibitor for Potential Treatment of Psoriasis, Other Autoimmune Disorders - - VTP-38543, Topical LXRβ Agonist, Unique Mechanism of Action for Potential Treatment of Atopic Dermatitis - - Vitae's Contour Drug Discovery Platform and Team Bolsters Allergan's Discovery Research Capabilities - DUBLIN and FORT WASHINGTON, Pa., Sept.... 
Download PDFPrinter Friendly Version
09/01/16Vitae Pharmaceuticals to Present at Wells Fargo Healthcare Conference
FORT WASHINGTON, Pa., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that Jeffrey Hatfield, President and Chief Executive Officer, will present a company overview at the 2016 Wells Fargo Securities Healthcare Conference on Thursday, September 8, 2016 at 1:10 p.m. EDT at the Westin Boston Waterfront. A live audio webcast of the presentation will be available via the "Investor Relations" page of the Vitae w... 
Download PDFPrinter Friendly Version
08/11/16Vitae Pharmaceuticals to Present at Wedbush PacGrow Healthcare Conference
FORT WASHINGTON, Pa., Aug. 11, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that Jeffrey Hatfield, President and Chief Executive Officer, will present a company overview at the 2016 Wedbush PacGrow Healthcare Conference on Wednesday, August 17, 2016 at 9:45 a.m. EDT at the Le Parker Meridien New York. A live audio webcast of the presentation will be available via the "Investor Relations" page of the Vitae website... 
Download PDFPrinter Friendly Version
08/10/16Vitae Pharmaceuticals Appoints Scott Applebaum as General Counsel and Corporate Secretary
FORT WASHINGTON, Pa., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced the appointment of Scott Applebaum as General Counsel and Corporate Secretary, effective immediately. Mr. Applebaum most recently served as Chief Legal Officer and Corporate Secretary at Medgenics, Inc., a genomics medicine company focused on rare pediatric diseases. “Scott’s extensive experience in providing legal and corporate complianc... 
Download PDFPrinter Friendly Version
08/03/16Vitae Pharmaceuticals Reports Second Quarter 2016 Operating and Financial Results
Proof-of-concept data for VTP-38543 expected in the fourth quarter of 2016 Conference call scheduled for 4:30 p.m. EDT today FORT WASHINGTON, Pa., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today reported its operating and financial results for the quarter ended June 30, 2016. Jeff Hatfield, President and Chief Executive Officer of Vitae, commented, “During the quarter, we made significant progress towards the comple... 
Download PDFPrinter Friendly Version
08/01/16Vitae Pharmaceuticals to Announce Second Quarter 2016 Financial Results on August 3, 2016
FORT WASHINGTON, Pa., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, will host a conference call on Wednesday, August 3, 2016 at 4:30 p.m. EDT to discuss second quarter 2016 financial results and recent operational highlights. A question-and-answer session will follow Vitae's remarks. To participate on the live call, please dial 844-423-9893 (domestic) or +1-716-247-5808 (international) and provide the conference ID 56375... 
Download PDFPrinter Friendly Version
07/27/16Vitae Pharmaceuticals Appoints Daniel M. Junius to Board of Directors
Bryan Roberts, Ph.D. steps down from board FORT WASHINGTON, Pa., July 27, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced the appointment of Daniel M. Junius to its board of directors, effective immediately. Mr. Junius recently retired as President and Chief Executive Officer of ImmunoGen, Inc., a biotechnology company that develops targeted anticancer therapeutics, a position he held since January 2009. “On behalf... 
Download PDFPrinter Friendly Version
06/14/16Vitae Pharmaceuticals to Present at JMP Securities Life Sciences Conference
FORT WASHINGTON, Pa., June 14, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that Richard Gregg, M.D., Chief Scientific Officer, will present a company overview at the JMP Securities Life Sciences Conference on Tuesday, June 21, 2016 at 1:00 p.m. EDT at the St. Regis New York. A live audio webcast of the presentation will be available via the "Investor Relations" page of the Vitae website, www.vitaepharma.com. A r... 
Download PDFPrinter Friendly Version
06/06/16Vitae Pharmaceuticals Announces Appointment of Carole Sable, M.D., as Chief Medical Officer
FORT WASHINGTON, Pa., June 06, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that Carole Sable, M.D., has been named Chief Medical Officer, effective immediately. Dr. Sable will oversee the clinical development of Vitae’s pipeline, including wholly owned mid-stage clinical assets VTP-43742, an oral RORyt inhibitor being developed for autoimmune disorders and currently being assessed in moderate to severe psoriasis, a... 
Download PDFPrinter Friendly Version
05/10/16Vitae Pharmaceuticals Reports First Quarter 2016 Operating and Financial Results
Proof-of-concept data for VTP-38543 expected in the second half of 2016 Conference call scheduled for 4:30 p.m. EDT today FORT WASHINGTON, Pa., May 10, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today reported its operating and financial results for the quarter ended March 31, 2016. Jeff Hatfield, President and Chief Executive Officer of Vitae, commented, “The highlight of the first quarter was the positive top-line results ... 
Download PDFPrinter Friendly Version
05/09/16Vitae Pharmaceuticals to Present at IMMUNOLOGY 2016
Poster to highlight positive Phase 1 data for RORγt inhibitor VTP-43742 FORT WASHINGTON, Pa., May 09, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that Gerard M. McGeehan, Ph.D., Vice President of Biology, will present a poster titled “Safety, tolerability, pharmacokinetics and pharmacodynamics of VTP-43742, a RORγt inhibitor, in normal healthy volunteers” at IMMUNOLOGY 2016, the American Association of Immunolog... 
Download PDFPrinter Friendly Version
05/03/16Vitae Pharmaceuticals to Announce First Quarter 2016 Financial Results on May 10, 2016
FORT WASHINGTON, Pa., May 03, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, will host a conference call on Tuesday, May 10, 2016 at 4:30 p.m. EDT to discuss first quarter 2016 financial results and recent operational highlights. A question-and-answer session will follow Vitae's remarks. To participate on the live call, please dial 844-423-9893 (domestic) or +1-716-247-5808 (international) and provide the conference ID 1781961 fiv... 
Download PDFPrinter Friendly Version
03/30/16Vitae Pharmaceuticals Closes Public Offering of Common Stock
FORT WASHINGTON, Pa., March 30, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced the completion of its underwritten public offering of 5,833,333 shares of its common stock at a price to the public of $6.00 per share. In connection with the offering, Vitae has granted the underwriters a 30-day option to purchase up to an additional 875,000 shares of its common stock on the same terms and conditions. The gross offering pr... 
Download PDFPrinter Friendly Version
03/24/16Vitae Pharmaceuticals Prices Public Offering of Common Stock
FORT WASHINGTON, Pa., March 24, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced the pricing of an underwritten public offering of 5,833,333 shares of its common stock at a price to the public of $6.00 per share. In connection with the offering, Vitae has granted the underwriters a 30-day option to purchase up to an additional 875,000 shares of its common stock on the same terms and conditions. Gross proceeds from the s... 
Download PDFPrinter Friendly Version
03/23/16Vitae Pharmaceuticals Proposes Public Offering of Common Stock
FORT WASHINGTON, Pa., March 23, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) (Vitae), a clinical-stage biotechnology company, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares in the offering are to be sold by Vitae, with net proceeds to be used to advance the clinical development of Vitae’s RORγt program, including, among other items, the completion of a 16-week Phase 2b clinical trial of VT... 
Download PDFPrinter Friendly Version
03/16/16Vitae Pharmaceuticals Achieves Proof-of-Concept with First-in-Class RORyt Inhibitor in Moderate to Severe Psoriasis
VTP-43742 demonstrated statistically significant efficacy and was well tolerated              Company plans to move VTP-43742 forward into 16-week study Conference call to discuss results at 5:00 p.m. ET, March 16, 2016 James Krueger, M.D., Ph.D., Head of the Laboratory for Investigative Dermatology at Rockefeller University, to join call FORT WASHINGTON, Pa., March 16, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announ... 
Download PDFPrinter Friendly Version
03/03/16Vitae Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Operating and Financial Results
Proof-of-concept data for VTP-43742 expected in the first quarter of 2016 Initiated proof-of-concept trial of VTP-38543 in patients with atopic dermatitis Conference call scheduled for 4:30 p.m. EST today FORT WASHINGTON, Pa., March 03, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today reported its operating and financial results for the fourth quarter and full year ended December 31, 2015. Jeff Hatfield, President and Chief E... 
Download PDFPrinter Friendly Version
02/25/16Vitae Pharmaceuticals to Announce Fourth Quarter and Full Year 2015 Financial Results on March 3, 2016
FORT WASHINGTON, Pa., Feb. 25, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, will host a conference call on Thursday, March 3, 2016 at 4:30 p.m. EST to discuss fourth quarter and full year 2015 financial results and recent operational highlights. A question-and-answer session will follow Vitae's remarks. To participate on the live call, please dial 844-423-9893 (domestic) or +1-716-247-5808 (international) and provide the confere... 
Download PDFPrinter Friendly Version
12/29/15Vitae Pharmaceuticals Doses First Patients in Phase 2a Proof-of-Concept Trial of VTP-38543 in Atopic Dermatitis
Top-Line Results Expected in the Second Half of 2016 FORT WASHINGTON, Pa., Dec. 29, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that it has dosed the first patients in its Phase 2a proof-of-concept clinical trial of VTP-38543 in atopic dermatitis (AD). VTP-38543 is the Company’s topical LXRβ selective agonist for the treatment of AD, a skin condition characterized by an intense itch / scratch cycle and driven by b... 
Download PDFPrinter Friendly Version
12/17/15Vitae Pharmaceuticals Reports Top-Line Results From Remaining Monotherapy Arm of Phase 2 Clinical Trial of BI187004 in Overweight Type 2 Diabetes Patients
FORT WASHINGTON, Pa., Dec. 17, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced top-line clinical efficacy results from the remaining monotherapy arm of Boehringer Ingelheim’s Phase 2 proof-of-concept trial of BI187004 (VTP-34072) in type 2 diabetes. This randomized, double-blind, placebo-controlled Phase 2 proof-of-concept trial assessed the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of BI... 
Download PDFPrinter Friendly Version
12/14/15Vitae Pharmaceuticals Announces Addition to the NASDAQ Biotechnology Index
FORT WASHINGTON, Pa., Dec. 14, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that it has been added to the NASDAQ Biotechnology Index (NASDAQ:NBI). The addition will become effective prior to the market open on Monday, December 21, 2015. Vitae is also included in the Russell 3000® and 2000® indices. The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ-listed securities that are cl... 
Download PDFPrinter Friendly Version
12/10/15Vitae Pharmaceuticals Opens Phase 2a Proof-of-Concept Trial of VTP-38543 in Atopic Dermatitis Patients
FORT WASHINGTON, Pa., Dec. 10, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced updated plans to begin clinical development of VTP-38543 with a four-week Phase 2a proof-of-concept trial that has been opened for patients with atopic dermatitis (AD). Previously, the Company had expected to initiate a Phase 1 clinical trial. The Company has started activities to initiate the Phase 2a trial and expects to begin dosing patient... 
Download PDFPrinter Friendly Version
11/24/15Vitae Pharmaceuticals to Present at 27th Annual Piper Jaffray Healthcare Conference
FORT WASHINGTON, Pa., Nov. 24, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that Jeffrey Hatfield, President and Chief Executive Officer, will present a company overview at the 27th Annual Piper Jaffray Healthcare Conference on Tuesday, December 1, 2015 at 9:00 a.m. EST at The Lotte New York Palace Hotel. A live audio webcast of the presentation will be available via the "Investor Relations" page of the Vitae webs... 
Download PDFPrinter Friendly Version
11/18/15Vitae Pharmaceuticals Announces Positive Top-Line Results From a Phase 1 Multiple Ascending Dose Trial of VTP-43742
Multiple ascending doses of VTP-43742 shown to be safe and generally well tolerated in healthy human volunteers Robust ex vivo biomarker response, suppressing secretion of pro-inflammatory IL-17A by more than 90 percent Top-line proof-of-concept clinical results from Phase 1 trial of VTP-43742 in psoriatic patients expected in the first quarter of 2016 FORT WASHINGTON, Pa., Nov. 18, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-sta... 
Download PDFPrinter Friendly Version
11/12/15REMINDER: Vitae Pharmaceuticals to Host Analyst and Investor Briefing
Scheduled for 7:00 a.m. EST on November 19, 2015 Presentations to begin at 7:15 a.m. EST FORT WASHINGTON, Pa., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, will host an Analyst and Investor Briefing on Thursday, November 19, 2015 from 7:00 to 9:00 a.m. EST in New York, NY. Presentations will begin at 7:15 a.m. EST and leading academic experts are scheduled to speak. For additional information and registration... 
Download PDFPrinter Friendly Version
11/10/15Vitae Pharmaceuticals to Present at Stifel 2015 Healthcare Conference
FORT WASHINGTON, Pa., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that Jeffrey Hatfield, President and Chief Executive Officer, will present a company overview at the Stifel 2015 Healthcare Conference on Tuesday, November 17, 2015 at 11:00 a.m. EST at The New York Palace Hotel. A live audio webcast of the presentation will be available via the "Investor Relations" page of the Vitae website, www.vitaephar... 
Download PDFPrinter Friendly Version
11/05/15Vitae Pharmaceuticals Reports Third Quarter 2015 Operating and Financial Results
Announces psoriasis as lead indication for VTP-43742 Conference call scheduled for 4:30 p.m. EST today FORT WASHINGTON, Pa., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company developing a robust and growing portfolio generated by its proprietary structure-based drug discovery platform, today reported its operating and financial results for the third quarter ended September 30, 2015. Jeff Hatfield, President and Chief Ex... 
Download PDFPrinter Friendly Version
11/02/15Vitae Pharmaceuticals to Announce Third Quarter 2015 Financial Results on November 5, 2015
FORT WASHINGTON, Pa., Nov. 2, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, will host a conference call on Thursday, November 5, 2015 at 4:30 p.m. EST to discuss third quarter 2015 financial results and recent operational highlights. A question-and-answer session will follow Vitae's remarks. To participate on the live call, please dial 844-423-9893 (domestic) or +1-716-247-5808 (international) and provide the conference ID 7014119... 
Download PDFPrinter Friendly Version
10/20/15Vitae Pharmaceuticals to Host Analyst and Investor Briefing
Scheduled for 7:00 a.m. EST on November 19, 2015 FORT WASHINGTON, Pa., Oct. 20, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company, will host an Analyst and Investor Briefing on Thursday, November 19, 2015 from 7:00 to 9:00 a.m. EST in New York, NY. For additional information and registration, please email vitae@westwicke.com or call 443-213-0506. A live audio webcast of the event will be available via the "Investor Relations" page... 
Download PDFPrinter Friendly Version
09/30/15Vitae Pharmaceuticals Appoints Dr. Karen Bernstein to Board of Directors
Charles W. Newhall, III Steps Down From Board FORT WASHINGTON, Pa., Sept. 30, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced the appointment of Karen Bernstein, Ph.D., to its board of directors, effective immediately. Dr. Bernstein is best known for co-founding and shaping BioCentury Publications Inc. into one of the biotechnology sector's most highly regarded sources of global industry intelligence. Dr. Bernstein step... 
Download PDFPrinter Friendly Version
09/29/15Vitae Pharmaceuticals Initiates Second Part of a Phase 1 Multiple Ascending Dose Study of VTP-43742 in Psoriatic Patients
Top-Line Proof-of-Concept Data in Psoriasis Patients Expected by the End of 2015 FORT WASHINGTON, Pa., Sept. 29, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that it has initiated the second part of its Phase 1 multiple ascending dose clinical trial of VTP-43742 in psoriatic patients. VTP-43742 is the Company's wholly owned and first-in-class RORγt inhibitor product candidate for the treatment of autoimmune disorders... 
Download PDFPrinter Friendly Version
09/22/15Vitae Pharmaceuticals to Ring the NASDAQ Stock Market Closing Bell
FORT WASHINGTON, Pa., Sept. 22, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that Jeff Hatfield, President and Chief Executive Officer, will ring the NASDAQ Closing Bell at the NASDAQ MarketSite in Times Square today at 4:00 p.m. ET. Mr. Hatfield will be joined by Vitae's executive leadership team to recognize the one-year anniversary of the Company's initial public offering (IPO). "I'm honored to ring the clo... 
Download PDFPrinter Friendly Version
09/08/15Vitae Pharmaceuticals Announces Positive Top-Line Results From Initial Phase 1 Study of First-in-Class RORyt Inhibitor VTP-43742 in Autoimmune Disorders
Single ascending doses of VTP-43742 safe and generally well-tolerated, demonstrated once-daily pharmacokinetics Robust ex vivo biomarker response, suppressing pro-inflammatory IL-17A by more than 90 percent FORT WASHINGTON, Pa., Sept. 8, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced positive top-line results from its Phase 1 single ascending dose clinical study of VTP-43742 in autoimmune disorders. VTP-4374... 
Download PDFPrinter Friendly Version
08/10/15Vitae Pharmaceuticals Announces Initiation of a Phase 1 Multiple Ascending Dose Study of VTP-43742 in Autoimmune Disorders
FORT WASHINGTON, Pa., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that it has initiated a Phase 1 multiple ascending dose clinical trial of VTP-43742, its wholly owned and first-in-class RORγt inhibitor product candidate for the treatment of autoimmune disorders, including psoriasis, psoriatic arthritis, ankylosing spondylitis, rheumatoid arthritis and multiple sclerosis, as well as numerous orphan indicatio... 
Download PDFPrinter Friendly Version
08/05/15Vitae Pharmaceuticals to Present at Wedbush PacGrow Healthcare Conference
FORT WASHINGTON, Pa., Aug. 5, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that Jeffrey Hatfield, President and Chief Executive Officer, will present a company overview at the 2015 Wedbush PacGrow Healthcare Conference on Wednesday, August 12, 2015 at 9:10 a.m. EDT at the Le Parker Meridien New York. A live audio webcast of the presentation will be available via the "Investor Relations" page of the Vitae website, ... 
Download PDFPrinter Friendly Version
08/04/15Vitae Pharmaceuticals Reports Second Quarter 2015 Operating and Financial Results
Multiple potential milestones in 2H 2015 Conference call scheduled for 4:30 p.m. EDT today FORT WASHINGTON, Pa., Aug. 4, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company developing a robust and growing portfolio generated by its proprietary structure-based drug discovery platform, reported today its operating and financial results for the second quarter ended June 30, 2015. "During the second quarter of 2015, we initiated a Ph... 
Download PDFPrinter Friendly Version
07/29/15Vitae Pharmaceuticals Appoints Dr. John M. Leonard to Board of Directors
FORT WASHINGTON, Pa., July 29, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced the appointment of John M. Leonard, M.D., to its board of directors, effective immediately. A 30-year biopharmaceutical industry veteran, Dr. Leonard served as Chief Scientific Officer and Senior Vice President of Research & Development at AbbVie, Inc. following its spin-out from Abbott Laboratories in 2013 until his retirement. While at AbbVi... 
Download PDFPrinter Friendly Version
07/28/15Vitae Pharmaceuticals to Announce Second Quarter 2015 Financial Results on August 4, 2015
FORT WASHINGTON, Pa., July 28, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, will host a conference call on Tuesday, August 4, 2015 at 4:30 p.m. EDT to discuss second quarter 2015 financial results and recent operational highlights. A question-and-answer session will follow Vitae's remarks. To participate on the live call, please dial 844-423-9893 (domestic) or +1-716-247-5808 (international) and provide the conference ID 94533069... 
Download PDFPrinter Friendly Version
07/27/15Vitae Pharmaceuticals and Boehringer Ingelheim to End Collaboration and License Agreement for BACE Inhibitors
Vitae Expects to Receive Rights to BI-1147560 / VTP-36951 Company to Assess Program to Determine Next Steps FORT WASHINGTON, Pa., July 27, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that Boehringer Ingelheim (BI) has notified Vitae that BI is ending the parties' collaboration and license agreement for orally-active beta secretase (BACE) inhibitors for the treatment and prevention of Alzheimer's disease and o... 
Download PDFPrinter Friendly Version
06/29/15Vitae Pharmaceuticals Announces Top-Line Results From Metformin Arm of Ongoing Phase 2 Clinical Trial of BI187004/VTP-34072 in Overweight Type 2 Diabetics
FORT WASHINGTON, Pa., June 29, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced top-line clinical efficacy results from the metformin arm of an ongoing Phase 2 proof-of-concept clinical trial of BI187004/VTP-34072 in the treatment of overweight type 2 diabetic patients. BI187004/VTP-34072 is a potential first-in-class 11β-hydroxysteroid dehydrogenase type 1 (11β HSD1) inhibitor that was discovered by Vitae and is currentl... 
Download PDFPrinter Friendly Version
06/29/15Vitae Pharmaceuticals Announces Initiation of a Phase 1 Single Ascending Dose Study of VTP-43742 in Autoimmune Disorders
FORT WASHINGTON, Pa., June 29, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced the initiation of a Phase 1 single ascending dose clinical trial of VTP-43742, the Company's wholly owned and potential first-in-class RORγt inhibitor for the treatment of autoimmune disorders, including psoriasis, multiple sclerosis, and various arthropathies, as well as rare and orphan disorders. This single ascending dose trial will ass... 
Download PDFPrinter Friendly Version
06/16/15Vitae Pharmaceuticals to Present at JMP Securities Life Sciences Conference
FORT WASHINGTON, Pa., June 16, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company developing a robust and growing portfolio generated by its proprietary structure-based drug discovery platform, today announced that Richard Morris, Chief Financial Officer, will present a company overview at the JMP Securities Life Sciences Conference on Tuesday, June 23, 2015 at 2:00 p.m. EDT at The St. Regis New York. A live audio webcast of the present... 
Download PDFPrinter Friendly Version
05/13/15Vitae Pharmaceuticals to Present at UBS Global Healthcare Conference
FORT WASHINGTON, Pa., May 13, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company developing a robust and growing portfolio generated by its proprietary structure-based drug discovery platform, today announced that Jeffrey Hatfield, President and Chief Executive Officer, will present a company overview at the UBS Global Healthcare Conference on Wednesday, May 20, 2015 at 12:30 p.m. EDT at the Sheraton New York Times Square Hotel. A live ... 
Download PDFPrinter Friendly Version
05/12/15Vitae Pharmaceuticals Reports First Quarter 2015 Operating and Financial Results
Multiple impending 2Q inflection points supported by enhanced cash position Conference call scheduled for 4:30 p.m. EDT today FORT WASHINGTON, Pa., May 12, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company developing a robust and growing portfolio generated by its proprietary structure-based drug discovery platform, reported today its operating and financial results for the first quarter ended March 31, 2015. "During the first ... 
Download PDFPrinter Friendly Version
05/06/15Vitae Pharmaceuticals to Present at Upcoming Meetings
FORT WASHINGTON, Pa., May 6, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company developing a robust and growing portfolio generated by its proprietary structure-based drug discovery platform, announced that it will be presenting new data on several of its product candidates for the treatment of autoimmune diseases, atopic dermatitis and acute coronary syndrome at upcoming scientific meetings. IMMUNOLOGY 2015: The American Association of... 
Download PDFPrinter Friendly Version
05/05/15Vitae Pharmaceuticals to Announce First Quarter 2015 Financial Results on May 12, 2015
FORT WASHINGTON, Pa., May 5, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company, will host a conference call on Tuesday, May 12, 2015 at 4:30 p.m. EDT to discuss first quarter 2015 financial results and recent operational highlights. A question-and-answer session will follow Vitae's remarks. To participate on the live call, please dial 844-423-9893 (domestic) or +1-716-247-5808 (international) and provide the conference ID 40302906 five... 
Download PDFPrinter Friendly Version
04/16/15Vitae Pharmaceuticals to Present at Keystone Symposia on Mechanisms of Pro-Inflammatory Diseases
FORT WASHINGTON, Pa., April 16, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company, today announced that Gerard M. McGeehan, Ph.D., Vice President, Discovery Biology, will deliver an oral presentation related to VTP-43742, Vitae's RORγt product candidate for the treatment of autoimmune diseases, at the Keystone Symposia on Mechanisms of Pro-Inflammatory Diseases, which is being held April 19-24 at the Resort at Squaw Creek in Olympic Valley... 
Download PDFPrinter Friendly Version
03/31/15Vitae Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Operating and Financial Results
Conference Call Scheduled for 8:30 a.m. EDT Today FORT WASHINGTON, Pa., March 31, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company, reported today its operating and financial results for the fourth quarter and full year ended December 31, 2014. "We continue to make significant progress in advancing our RORγt program with our lead proprietary candidate, VTP-43742 for the treatment of autoimmune disorders, towards initiation of a Phase... 
Download PDFPrinter Friendly Version
03/27/15Vitae Pharmaceuticals to Announce Fourth Quarter and Full Year 2014 Financial Results on March 31, 2015
FORT WASHINGTON, Pa., March 27, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company, will host a conference call on Tuesday, March 31, 2015 at 8:30 a.m. EDT to discuss fourth quarter and full year 2014 financial results and recent operational highlights. A question-and-answer session will follow Vitae's remarks. To participate on the live call, please dial 844-423-9893 (domestic) or +1-716-247-5808 (international) and provide the confere... 
Download PDFPrinter Friendly Version
02/27/15Vitae Pharmaceuticals to Present at Cowen and Company 35th Annual Health Care Conference
FORT WASHINGTON, Pa., Feb. 27, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company, today announced that Jeffrey Hatfield, President and Chief Executive Officer, will present a company overview at the Cowen and Company 35th Annual Health Care Conference on Tuesday, March 3, 2015 at 8:00 a.m. EST at the Boston Marriott Copley Place. A live audio webcast of the presentation will be available via the "Investor Relations" page of the Vitae w... 
Download PDFPrinter Friendly Version
02/26/15BACE Inhibitor BI 1181181 Voluntarily Put on Temporary Clinical Hold for Safety Evaluation
FORT WASHINGTON, Pa., Feb. 26, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company, today announced that its partner Boehringer Ingelheim has voluntarily placed BI 1181181 on a temporary clinical hold, and has notified regulatory agencies of its decision. BI 1181181 is an orally-active beta secretase (BACE) inhibitor being evaluated in Phase 1 clinical trials for the treatment and prevention of Alzheimer's disease. This action was taken to f... 
Download PDFPrinter Friendly Version
01/28/15Vitae Pharmaceuticals Announces Exercise of Underwriters' Option to Purchase Additional Shares and Closing of Follow-on Public Offering of Common Stock
FORT WASHINGTON, Pa., Jan. 28, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical stage biotechnology company, today announced the closing of its previously announced underwritten public offering. A total of 3,450,000 shares of its common stock were sold in the offering at a price to the public of $11.90 per share. The shares include 450,000 shares of common stock sold pursuant to the underwriters' option to purchase additional shares, which was exercised in full. Net... 
Download PDFPrinter Friendly Version
01/23/15Vitae Pharmaceuticals Announces Pricing of Follow-on Public Offering of Common Stock
FORT WASHINGTON, Pa., Jan. 23, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical stage biotechnology company, today announced the pricing of its follow-on public offering of 3,000,000 shares of its common stock at $11.90 per share. All shares of common stock to be sold in the offering are being offered by Vitae. Vitae has also granted the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock. The offering is expected to close... 
Download PDFPrinter Friendly Version
01/20/15Vitae Pharmaceuticals Launches Proposed Follow-on Public Offering of Common Stock
FORT WASHINGTON, Pa., Jan. 20, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical stage biotechnology company, today announced that it has commenced a proposed follow-on public offering of 3,000,000 shares of its common stock. All shares of common stock to be sold in the offering will be offered by Vitae. Vitae also expects to grant the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock in the public offering. Stifel, BMO C... 
Download PDFPrinter Friendly Version
12/23/14Vitae Pharmaceuticals Added to Russell 2000(R) and Russell 3000(R) Indexes
FORT WASHINGTON, Pa., Dec. 23, 2014 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company, today announced that it has been added to the Russell 2000® and Russell 3000® indexes, effective as of the close of the market on Friday, December 19, 2014 and as part of the quarterly Initial Public Offering (IPO) update to the Russell indexes. Russell indexes are widely used by investment managers and institutional investors for index funds and as bench... 
Download PDFPrinter Friendly Version
12/08/14Vitae Pharmaceuticals Among 2014 Best Places to Work in PA
Marks Fifth Consecutive Year Vitae Has Made the List FORT WASHINGTON, Pa., Dec. 8, 2014 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company, today announced it was named one of the 100 Best Places to Work in PA for the fifth consecutive year. "I'm proud that Vitae has been recognized as a great place to work in Pennsylvania, now for five years in a row," said Jeffrey Hatfield, President and Chief Executive Officer of Vitae. "It's a testament... 
Download PDFPrinter Friendly Version
11/12/14Vitae Pharmaceuticals Reports Third Quarter 2014 Operating and Financial Results
Conference Call Scheduled for 4:30 p.m. EST Today FORT WASHINGTON, Pa., Nov. 12, 2014 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company, reported today its operating and financial results for the third quarter ended September 30, 2014. "The successful completion of our initial public offering in September provides us with additional capital to advance our proprietary pipeline, and, we believe, to achieve a number of key milestones," sai... 
Download PDFPrinter Friendly Version
11/12/14Vitae Pharmaceuticals to Present at Stifel 2014 Healthcare Conference
FORT WASHINGTON, Pa., Nov. 12, 2014 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company, today announced that Jeffrey Hatfield, President and Chief Executive Officer, will present a company overview at the Stifel 2014 Healthcare Conference on Wednesday, November 19, 2014 at 4:45 p.m. EST in New York City. A live audio webcast of the presentation will be available via the "Investor Relations" page of the Vitae website, www.vitaepharma.com. A r... 
Download PDFPrinter Friendly Version
11/05/14Vitae Pharmaceuticals to Announce Third Quarter 2014 Financial Results on November 12, 2014
FORT WASHINGTON, Pa., Nov. 5, 2014 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company, will host a conference call on Wednesday, November 12, 2014 at 4:30 p.m. EST to discuss third quarter 2014 financial results and recent operational highlights. A question-and-answer session will follow Vitae's remarks. To participate on the live call, please dial 844-423-9893 (domestic) or +1-716-247-5808 (international) and provide the conference ID 32241... 
Download PDFPrinter Friendly Version
10/27/14Vitae Pharmaceuticals Announces Exercise of Underwriters' Option to Purchase Additional Shares of Initial Public Offering
FORT WASHINGTON, Pa., Oct. 27, 2014 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical stage biotechnology company, today announced that the underwriters of its previously announced initial public offering (IPO) of common stock have exercised in full their option to purchase 1,031,250 shares of common stock at the IPO price of $8.00 per share, less underwriting discounts. After giving effect to the over-allotment closing, the aggregate net proceeds to Vitae from the IPO, a... 
Download PDFPrinter Friendly Version
10/23/14Positive Top-Line Results Achieved From Two Phase 1 Clinical Trials of BACE Inhibitor BI1181181/VTP-37948 in Alzheimer's Disease
BI1181181/VTP-37948 Demonstrated Greater Than 80% Reduction of an Alzheimer's Disease Biomarker, the Cerebral Spinal Fluid Amyloid Beta Levels BI1181181/VTP-37948 Was Safe and Generally Well-Tolerated With a Profile Supporting Once-Daily Dosing FORT WASHINGTON, Pa., Oct. 23, 2014 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company, today announced positive top-line results from clinical trials in treatment and prevention... 
Download PDFPrinter Friendly Version
09/29/14Vitae Pharmaceuticals Announces Closing of Initial Public Offering
FORT WASHINGTON, Pa., Sept. 29, 2014 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical stage biotechnology company, today announced the closing of its initial public offering of 6,875,000 shares of common stock at an initial public offering price of $8.00 per share. The aggregate net proceeds to Vitae, after underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $48.4 million. As previously reported, Vitae Pharmaceuticals ... 
Download PDFPrinter Friendly Version
09/24/14Vitae Pharmaceuticals Announces Pricing of Initial Public Offering
FORT WASHINGTON, Pa., Sept. 24, 2014 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc., a clinical stage biotechnology company, today announced the pricing of its initial public offering of 6,875,000 shares of common stock at an initial public offering price of $8.00 per share. The shares are expected to begin trading on The NASDAQ Global Market on September 24, 2014 under the ticker symbol "VTAE." In addition, Vitae Pharmaceuticals has granted the underwriters a 30-day option to purchase up to an... 
Download PDFPrinter Friendly Version
02/20/14Vitae Pharmaceuticals Earns $14 Million Milestone Payment from Boehringer Ingelheim in Alzheimer’s Collaboration.
Milestone achieved for BI’s initiation of Phase 1 study in beta-secretase (BACE) inhibitor program FORT WASHINGTON, PA – February 20, 2014 – Vitae Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and advancing novel, small molecule, bestin-class compounds, announced today that it has earned a $14 million milestone payment from Boehringer Ingelheim (BI) for BI’s initiation of a Phase 1 clinical trial in the companies’ bet... 
Download PDFPrinter Friendly Version
10/29/13Vitae Pharmaceuticals named one of the Best Places to Work in PA 2013
Announcement marks fourth consecutive year Vitae has made the list FORT WASHINGTON, PA – October 29, 2013 – Vitae Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company discovering and developing novel, small molecule, best-in-class compounds, today announced it was named one of Central Penn Business Journal’s 100 Best Places to Work in PA for 2013. The company will be honored at a reception on Thursday, Dec. 5, at the Lancaster County Convention ... 
Download PDFPrinter Friendly Version
10/21/13Vitae Pharmaceuticals, Dow Corning, And Johnson & Johnson Share Their Policies For Attracting And Retaining The Best Employees.
... 
Printer Friendly Version
08/01/13Vitae’s executive team talks about innovation in drug discovery on The In Vivo Blog
One of the best things about having time to sit down with a company's executive team and discuss matters such as pipeline and business strategy at leisure is the chance to intersperse more philosophical questions that address how a company views itself and the work environment it tries to provide. In meeting a few weeks ago with the executive team at Vitae Pharmaceuticals near Philadelphia for a profile in "The Pink Sheet," I got more information than I could process on the firm... 
Download PDFPrinter Friendly Version
07/29/13Read The Pink Sheet’s profile of Vitae Pharmaceuticals
... 
Printer Friendly Version
06/12/13Vitae Pharmaceuticals is ranked #2 in The Scientist magazine’s annual “Best Places to Work” survey
Vitae ranked second overall in life sciences industry; highest-ranked U.S. company Survey measured responses of more than 200 companies worldwide Fort Washington, PA, June 12, 2013 – Vitae Pharmaceuticals, Inc., a clinical‐stage biopharmaceutical company discovering and developing novel, small molecule, best‐in‐class compounds, today announced that the company ranked second among life sciences companies in the 11th annual Best Places to Work in Industry survey conducted by The Scient... 
Download PDFPrinter Friendly Version
06/04/13Progress update of Vitae’s RORγt inhibitor program
Robust efficacy results achieved in multiple sclerosis mouse model with record-breaking speed Vitae’s time from initiation of program to animal proof-of-principle with qualified lead has consistently been less than 18 months FORT WASHINGTON, PA – June 4, 2013 – Vitae Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company discovering and developing novel, small molecule, first- and bestin-class compounds, today announced that it has achieved animal proof-of-principle of ... 
Download PDFPrinter Friendly Version
02/20/13Read Vitae CEO Jeff Hatfield’s views on the Life Sciences market in the Grant Thornton Life Sciences spotlight
... 
Printer Friendly Version
09/06/12Vitae Pharmaceuticals Announces Promising Data for VTP-4, Drug Candidate Advancing toward Clinical Testing for the Treatment of Atherosclerosis
... 
Printer Friendly Version
07/18/12Vitae Pharmaceuticals to present the poster, ” A Novel LXRbeta-selective Partial Agonist Increases the ApoE-ABCA1 Pathway and Decreases Hippocampal Abeta in Cynomolgus Monkeys without Increasing Liver Triglycerides,” at the 2012 Alzheimer’s Association International Conference (AAIC) in Vancouver, BC.
... 
Printer Friendly Version
01/19/12Vitae Pharmaceuticals secures $15M in debt financing to support the progress of their discovery pipeline
... 
Printer Friendly Version
01/05/12Vitae Pharmaceuticals to present at the 30th Annual JP Morgan Healthcare Conference in San Francisco on January 12, 2012
Fort Washington, PA, January 5, 2012 ‐‐ Vitae Pharmaceuticals today announced it will present at the JP Morgan Healthcare Conference on Thursday, January 12, 2012 at 9:30 a.m. Pacific Time in San Francisco, CA. Vitae's President and Chief Executive Officer, Jeffrey Hatfield, will provide an overview on the company and its clinical programs, including VTP‐27999 for chronic kidney disease. About Vitae Pharmaceuticals Vitae Pharmaceuticals is a clinical‐stage biopharmaceutical comp... 
Download PDFPrinter Friendly Version
11/11/11Vitae Pharmaceuticals highlights VTP-27999 data in two late breaker poster presentations at the American Society of Nephrology’s Kidney Week 2011
Fort Washington, PA, November 11, 2011 -- Vitae Pharmaceuticals today announced results from the Company’s early stage clinical program for VTP‐27999, a novel, potent and selective renin inhibitor. Data from two separate studies highlight the potential for VTP‐27999 to offer a significant clinical benefit to patients living with chronic kidney disease. The data will be presented at Kidney Week 2011, the annual meeting of the American Society of Nephrology (ASN) being held in Philadel... 
Download PDFPrinter Friendly Version
10/05/11Vitae President and CEO Jeff Hatfield has been elected to the Board of Directors of the Biotechnolog Industry Organization
FORT WASHINGTON, Pa.— Vitae Pharmaceuticals today announced Jeffrey Hatfield, the Company’s President and Chief Executive Officer, was elected to the Board of Directors of the Biotechnology Industry Organization (BIO), effective immediately. During his 2011‐2012 tenure on the BIO Board, Mr. Hatfield will initially serve on two Governing Committees: the Intellectual Property committee and the Emerging Company Section Capital Formation committee. Mr. Hatfield commented, “I am honored... 
Download PDFPrinter Friendly Version
06/27/11Vitae Reports Positive Clinical Data in Chronic Kidney Disease Program at the American Diabetes Association’s 71st Scientific Sessions
- Phase I Findings for VTP-27999 Show Potential for Superior Renal Protection - - Phase 2b Study Planned for First Quarter 2012 - Fort Washington, PA, June 27, 2011 -- Vitae Pharmaceuticals today announced results of a Phase I clinical study in healthy volunteers demonstrating the Company’s lead compound, VTP-27999, significantly reduced the activity of the renin-angiotensin-aldosterone system (RAAS) in the kidney. The RAAS pathway is considered to have a central role in the progress... 
Download PDFPrinter Friendly Version
04/28/11Vitae Pharmaceuticals is named one of the Top Ten Best Places to Work by The Scientist magazine
Fort Washington, PA, April 28, 2011 – Vitae Pharmaceuticals announced today that the Company is ranked #6 in The Scientist magazine’s "Best Places to Work in Industry" ninth annual survey. Survey respondents were asked to assess their working environment according to 43 criteria in eight different categories, including Research Environment, Integrity, Job Satisfaction, and Training and Development. Survey respondents cited the research environment and company management at Vitae as l... 
Download PDFPrinter Friendly Version
12/02/10Vitae Pharmaceuticals is named one of the Best Places to Work in Pennsylvania
Fort Washington, PA, December 2, 2010 -- Vitae Pharmaceuticals announced today that the Company has been named one of the 100 Best Places to Work in PA for 2010. The awards program, created in 2000, is one of the first statewide programs of its kind in the country. The program is a public/private partnership between Team Pennsylvania Foundation, the Pennsylvania Department of Community and Economic Development and the Central Penn Business Journal. Vitae President and CEO Jeffrey Ha... 
Download PDFPrinter Friendly Version
09/29/10Vitae Pharmaceuticals’ President and CEO Jeffrey Hatfield Recognized by the Pennsylvania Life Sciences Awards Program as a CEO of the Year
Fort Washington, PA, September 29, 2010 --Vitae Pharmaceuticals announced today that the inaugural, Pennsylvania-area LifeSciences Awards program has recognized President and CEO Jeffrey Hatfield as a Life Sciences CEO of the Year. Vitae is a clinical-stage biopharmaceutical company building a portfolio of novel, small molecule, best-in-class compounds that address large markets with significant unmet medical needs, including chronic kidney disease, diabetes, Alzheimer's disease and at... 
Download PDFPrinter Friendly Version
06/15/09Boehringer Ingelheim and Vitae Pharmaceuticals announce a major collaboration to research and develop novel treatments for Alzheimer’s disease
Contact: Kathryn Morris KMorrisPR +1 845-635-9828   Julia Meyer-Kleinmann Boehringer Ingelheim GmbH +49 6132 77 8271 Companies to advance beta-secretase (BACE) inhibitors, which hold potential for slowing the progression of this devastating neurodegenerative disease Fort Washington, Pennsylvania and Ingelheim, Germany –June 15, 2009– Boehringer Ingelheim and Vitae Pharmaceuticals, Inc., announced today that they have entered into a signific... 
Download PDFPrinter Friendly Version
10/28/08Vitae Pharmaceuticals Secures $13 Million In Debt Financing
Contact: Kathryn Morris KMorrisPR 845-635-9828 FORT WASHINGTON, PA– October 28, 2008 - Vitae Pharmaceuticals, Inc., an emerging pharmaceutical company dedicated to the discovery and development of innovative small molecule medicines, announced today that it has further strengthened its operating runway by entering into a $13 million loan agreement with Silicon Valley Bank and Oxford Finance Corporation. “These funds will support the initial clinical development of our potentia... 
Download PDFPrinter Friendly Version
03/05/08Vitae Pharmaceuticals Appoints Richard Gregg, M.D. as Chief Scientific Officer
Contact: Kathryn Morris KMorrisPR 845-635-9828 Brings extensive translational medicine experience to advance Vitae programs into clinic Fort Washington, Pennsylvania – March 5, 2008 – Vitae Pharmaceuticals, Inc., an emerging pharmaceutical company dedicated to the discovery and development of innovative small molecule medicines, announced today the appointment of Richard Gregg, M.D. as Chief Science Officer. Dr. Gregg comes to Vitae from Bristol Myers-Squibb where he w... 
Download PDFPrinter Friendly Version
10/15/07Vitae Pharmaceuticals and Boehringer Ingelheim Announce a Major Collaboration to Develop and Commercialize Novel Treatments for Diabetes and Metabolic Diseases
Contact: Kathryn Morris KMorrisPR +1 845-635-9828   Julia Meyer-Kleinmann Boehringer Ingelheim GmbH +49 6132 77 8271 Companies to advance 11beta-HSD1 inhibitors for diabetes and potentially other metabolic syndrome related indications Fort Washington, Pennsylvania and Ingelheim, Germany – October 15, 2007– Boehringer Ingelheim and Vitae Pharmaceuticals, Inc., announced today that they have established a major collaboration to develop and... 
Download PDFPrinter Friendly Version